Hexapharmatec Co. Ltd. has discovered new transcription factor EB (TFEB) inducers described as potentially useful for the treatment of colitis, kidney and hepatic fibrosis.
Yaoya Technology (Shanghai) Co. Ltd. has discovered new pyrimidothiopyrandione GTPase KRAS G12D mutant inhibitors potentially useful for the treatment of cancer.
Blueprint Medicines Corp. has identified new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a cyclin-dependent kinase 4 (CDK4)-targeting moiety potentially useful for the treatment of cancer.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized new Kelch-like ECH-associated protein 1 (KEAP1) activators and nuclear factor erythroid 2-related factor 2 (NRF2) degradation inducers potentially useful for the treatment of cancer.
Jiangxi Kerui Pharmaceutical Co. Ltd. has disclosed new prodrugs of fungal GPI-anchored wall transfer protein 1 (GWT1) inhibitors potentially useful for the treatment of fungal infections.
Changchun Genescience Pharmaceuticals Co. Ltd. has synthesized new molecular glue degraders comprising E3 ubiquitin-protein ligase-binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. They are described as potentially useful for the treatment of ulcerative colitis, Crohn’s disease, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and myasthenia gravis.
RSS